Author
Listed:
- R Krejci
(Ceva Sante Animale, Libourne Cedex, France)
- P Trampus
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- A Csagola
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- T Szalai
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- N Palmai
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- A Toth
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- N Terenyi
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- Z Nagy
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- NA Szeplaki
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- G Somogyi
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- T Barna
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- E Rausch
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- Z Penzes
(Ceva-Phylaxia Zrt., Budapest, Hungary)
- M Szaszko
(TargetEx Biosciences Ltd., Dunakeszi, Hungary)
- Z Lorincz
(TargetEx Biosciences Ltd., Dunakeszi, Hungary)
Abstract
Mycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination against these two pathogens helps mitigate their impact on pig health and performance. The use of ready-to-mix or ready-to-use (RTU) vaccines targeting PCV-2a or PCV-2a/b and M. hyo is a common practice. This study aimed to evaluate the efficacy of a novel RTU vaccine containing PCV-2d and M. hyo antigens under experimental conditions. Several challenge trials were conducted using PCV-2a, PCV-2b, PCV-2d, and M. hyo to assess the level of protection conferred against different PCV-2 genotypes and M. hyo, as well as to determine the duration of protection. This study demonstrated that the bivalent PCV-2/M. hyo vaccine induces both early and long-lasting protection against infections caused by M. hyo and PCV-2. In addition, cross-protection against the three major PCV-2 genotypes was confirmed.
Suggested Citation
R Krejci & P Trampus & A Csagola & T Szalai & N Palmai & A Toth & N Terenyi & Z Nagy & NA Szeplaki & G Somogyi & T Barna & E Rausch & Z Penzes & M Szaszko & Z Lorincz, 2025.
"Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions,"
Veterinární medicína, Czech Academy of Agricultural Sciences, vol. 70(6), pages 196-202.
Handle:
RePEc:caa:jnlvet:v:70:y:2025:i:6:id:6-2025-vetmed
DOI: 10.17221/6/2025-VETMED
Download full text from publisher
As the access to this document is restricted, you may want to
for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:caa:jnlvet:v:70:y:2025:i:6:id:6-2025-vetmed. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Ivo Andrle (email available below). General contact details of provider: https://www.cazv.cz/en/home/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.